专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

51. 发明申请

WO2006093547A3 NOVEL LIPOXYGENASE INHIBITORS 审中-公开
标题翻译：新型LIPOXYGENASE抑制剂
公开(公告)号：WO2006093547A3
公开(公告)日：2007-02-22
申请号：PCT/US2005044360
申请日：2005-12-09
申请人： GALILEO PHARMACEUTICALS INC , ZHANG WEI , CHEN JIAN
发明人： ZHANG WEI , CHEN JIAN
IPC分类号： C07D207/10 , A61K31/40 , A61K31/445 , C07D211/60
CPC分类号： A61K8/498 , A61K31/353 , A61K2800/782 , A61Q19/00 , C07D311/22 , C07D311/68 , C07D311/70 , C07D335/06
摘要： The present invention is concerned with certain novel derivatives of Formula (I): wherein X and R 1 to R 10 are as described in the specification, and where either R 5 is OH, -NR d OR a or NR d -NR b R c , or R 7 is -NR d OR a or NR d -NR b R c , or C=R 7 R 8 is C=NOR a or C=N-NR b R c , which may be useful in the manufacture of pharmaceutical compositions for treating disorders mediated by lipoxygenases. They may also be useful in the manufacture of pharmaceutical formulations for the treatment of lipoxygenase mediated disorders.
摘要翻译：本发明涉及式（I）的某些新型衍生物：其中X和R 1至R 10如说明书所述，并且其中R 0 > 5 是OH，-NR d，或O，或NR d，-NR b，或者R 7是-NR 11或-NR 11或-NR 11 或者C = R 7 R 8是C = NOR a S / O， >或C = N-NR B，其可用于制备用于治疗由脂肪氧合酶介导的病症的药物组合物。它们也可用于制备用于治疗脂氧合酶介导的病症的药物制剂。

52. 发明申请

WO2005081710A3 OXIDE FILMS WITH NANODOT FLUX PINNING CENTERS 审中-公开
标题翻译：带有NANODOT FLUX PINNING CENTER的氧化物膜
公开(公告)号：WO2005081710A3
公开(公告)日：2006-06-22
申请号：PCT/US2004038025
申请日：2004-11-15
申请人： AMERICAN SUPERCONDUCTOR CORP , RUPICH MARTIN W , KODENKANDATH THOMAS , ZHANG WEI , LI XIAOPING
发明人： RUPICH MARTIN W , KODENKANDATH THOMAS , ZHANG WEI , LI XIAOPING
IPC分类号： B01J29/00 , H01L39/24 , B05D5/12 , H02L39/24
CPC分类号： H01L39/2483 , H01L39/2425
摘要： A method for producing a thin film includes disposing a precursor solution onto a substrate to form a precursor film. The precursor solution contains precursor components to a rare-earth/alkaline-earth-metal/transition-metal oxide including a salt of a rare earth element, a salt of an alkaline earth metal, and a salt of a transition metal in one or more solvents, wherein at least one of the salts is a fluoride-containing salt. The precursor solution also contains an additive component comprising one or more metal compounds capable of forming a second phase nanoparticle, either alone or in combination with one or more of the precursor components of the precursor solution or a dopant component comprising one or more metal compounds capable of substituting for an element of the rare-earth/alkaline-earth-metal/transition-metal oxide, and treating the precursor film to form an intermediate metal oxyfluoride including the rare earth, the alkaline earth metal, the transition metal and the additive metal or dopant metal of the precursor solution.
摘要翻译：制造薄膜的方法包括将前体溶液设置在基板上以形成前体膜。前体溶液含有稀土/碱土金属/过渡金属氧化物的前体成分，所述稀土/碱土金属/过渡金属氧化物包括稀土元素的盐，碱土金属的盐和过渡金属的盐在一个或多个溶剂，其中至少一种盐是含氟化物的盐。前体溶液还包含添加剂组分，其包含一种或多种能够形成第二相纳米颗粒的金属化合物，单独或与前体溶液的一种或多种前体组分或包含一种或多种金属化合物的掺杂剂组分组合代替稀土/碱土金属/过渡金属氧化物的元素，并处理前体膜以形成包括稀土，碱土金属，过渡金属和添加金属的中间体金属氟氧化物或前体溶液的掺杂剂金属。

53. 发明申请

WO2005112931A3 METHODS RELATED TO THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY CONDITIONS 审中-公开
标题翻译：与治疗神经细胞和炎症条件相关的方法
公开(公告)号：WO2005112931A3
公开(公告)日：2006-06-01
申请号：PCT/US2005016691
申请日：2005-05-12
申请人： US GOV HEALTH & HUMAN SERV , HONG JAU-SHYONG , QIN LIYA , LI GUORONG , BLOCK MICHELLE , ZHANG WEI , CHEN PO-SEE , PENG GIIA-SHUEN
发明人： HONG JAU-SHYONG , QIN LIYA , LI GUORONG , BLOCK MICHELLE , ZHANG WEI , CHEN PO-SEE , PENG GIIA-SHUEN
IPC分类号： A61K31/485 , A61K38/00 , A61K38/06 , A61K38/33 , A61P29/00
CPC分类号： A61K38/08 , A61K31/19 , A61K31/46 , A61K31/485 , A61K38/06 , A61K38/33
摘要： The invention includes methods of neuroprotection, inducing release of neurotrophic factors, inhibiting the over-activation of innate immune cells, attenuating the toxin-induced death and/or damage of tissues, reducing inflammation, treating an inflammation-related condition, and inhibiting NADPH oxidase, that includes contacting or administering an effective amount of at least one compound of the invention that include: valproic acid, sodium butyrate, and salts thereof; opioid peptides; a peptide comprising the tripeptide GGF; and morphinans, such as naloxone, naltrexone, 3-hydroxy-morphinan and dextromethorphan.
摘要翻译：本发明包括神经保护的方法，诱导神经营养因子的释放，抑制先天免疫细胞的过度激活，减轻毒素诱导的死亡和/或组织损伤，减少炎症，治疗炎症相关病症和抑制NADPH氧化酶包括接触或施用有效量的至少一种本发明的化合物，其包括：丙戊酸，丁酸钠及其盐; 阿片肽包含三肽GGF的肽; 和吗啡，如纳洛酮，纳曲酮，3-羟基吗啡喃和右美沙芬。

54. 发明申请

WO0187992A3 IONICALLY AND COVALENTLY CROSS-LINKED POLYMERS AND POLYMER MEMBRANES 审中-公开
标题翻译：共价键和离子交联聚合物和聚合物膜
公开(公告)号：WO0187992A3
公开(公告)日：2002-05-23
申请号：PCT/EP0105644
申请日：2001-05-17
申请人： UNIV STUTTGART INST FUER CHEMI , KERRES JOCHEN , ZHANG WEI , TANG CHY MING
发明人： KERRES JOCHEN , ZHANG WEI , TANG CHY-MING
IPC分类号： C08J5/18 , C08F8/44 , C08G85/00 , H01M8/02 , C08G75/00 , B01D71/06 , C08G75/23 , C08J5/22
CPC分类号： C08F8/44
摘要： The present invention relates to ionically and covalently cross-linked polymers and polymer membranes having recurrent units of the general formula (1), wherein Q is a link, oxygen, sulfur, (2) or (3) and the R radical is a divalent radical of an aromatic or heteroaromatic compound, and which are characterized in that a) R radical comprises at least partially substituents of general formula (4A), (4B), (4C), (4D), (4E), (4F), (4G) and/or (4H), b) R radical comprises at least partially substituents of the general formula (5A) and/or (5B) and/or the R radical is at least partially a group of the general formula (5C) and/or (5D) and c) the R radical comprises at least partially bridges of the general formula (6) linking at least to R radicals together, R1, R2, R3, R4, R5, M, X, Y, Z and m having the herein-mentioned meanings.
摘要翻译：所述verliegende发明涉及共价和离子交联聚合物，其包括以下通式的重复单元（式1），（1）其中，Q是键，氧，硫，（式2）或（2）（式3）和（3）的 R是基团的芳族或杂芳族化合物，其特征在于在二价在于：a）基团R，在通式的部分取代基（4A），（4B），（4C），（4D），（4E），至少（ 4F），（4G）和/或（4H）包括（配方）（4A）（配方）（4B）（配方）（4C）（配方）（4D）（配方）（4E）。（式）（4F）（配方）（4G）（配方）（4H）b）中基团R具有以下通式的部分取代基（5A）和/或（5B），（式）（5A）（配方）至少（ 5B）和/或基团R，至少teiweise的基团，通式（5C）和/或（5d）的（配方）（5A）（配方）（5B），以及c）基团R至少部分地桥接所述通式（ 6）（配方）（6），该至少两个基团R彼此结合，其中R <1>，R <2>，R <3>，R <4>和R <5>，M，X，Y， Z和m被再现的描述。

55. 发明申请

WO9950424A3 FUSION PROTEIN COMPRISING A SEQUENCE FROM A MAJOR COAT PROTEIN OF A PAPOVAVIRUS 审中-公开
标题翻译：融合蛋白包含来自斑马鱼的主要涂层蛋白的序列
公开(公告)号：WO9950424A3
公开(公告)日：1999-12-02
申请号：PCT/GB9900978
申请日：1999-03-29
申请人： STANLEY MARGARET ANNE , ZHANG WEI
发明人： STANLEY MARGARET ANNE , ZHANG WEI
IPC分类号： A61K39/00 , C07K14/025 , C12N7/04 , C12N15/62 , A61K39/12 , C07K19/00 , C12N5/10 , C12N7/01 , C12N7/02
CPC分类号： C07K14/005 , A61K39/00 , C07K2319/00 , C12N7/00 , C12N2710/14143 , C12N2710/20022 , C12N2710/20023
摘要： Modified virus-like particles (VLPs) can comprise fusion proteins having sequence from a major coat protein of a papovavirus, e.g. L1 protein of HPV 16 or 18, in which the N-terminal of the sequence derived from the major coat protein is fused to a further peptide sequence. The VLPs can contain a full sequence of an L1 protein, or an L1 sequence with an N-terminal deletion, or an L1 sequence with an aminoacid substitution mutation, and optionally a C-terminal L1 sequence deletion. The peptide sequence fused to the N-terminal can be immunogenic e.g. from a protein of a pathogen such as a virus. The further peptide sequence can provide a binding domain for affinity purification of the VLP. Modified VLPs can retain the native conformation of the VLP structure while also presenting to the immune system of a subject immunised with the modified VLPs an epitope present on an N-terminal extension of the major coat protein sequence. Corresponding polynucleotides, expression vectors, plasmids, vectors and cells containing such polynucleotides are disclosed.
摘要翻译：修饰的病毒样颗粒（VLP）可以包含具有来自乳头瘤病毒的主要外壳蛋白的序列的融合蛋白，例如。 HPV 16或18的L1蛋白质，其中源自主要外壳蛋白的序列的N末端与另一个肽序列融合。 VLP可以含有L1蛋白或具有N-末端缺失的L1序列或具有氨基酸取代突变的L1序列和任选的C末端L1序列缺失的完整序列。融合到N-末端的肽序列可以是免疫原性的来自病原体如蛋白质的病毒。另外的肽序列可以提供VLP的亲和纯化的结合结构域。修饰的VLP可以保留VLP结构的天然构象，同时还向被修饰的VLP免疫的受试者的免疫系统呈递存在于主要外壳蛋白序列的N末端延伸上的表位。公开了相应的多核苷酸，表达载体，质粒，载体和含有这种多核苷酸的细胞。

56. 发明申请

WO2013010677A3 DEVICE FOR DETERMINING THE CONCENTRATION OF A BLOOD CONSTITUENT IN A TUBE LINE 审中-公开
标题翻译：一种用于确定血液的物质的浓度，软管组件
公开(公告)号：WO2013010677A3
公开(公告)日：2013-06-06
申请号：PCT/EP2012003087
申请日：2012-07-20
申请人： FRESENIUS MEDICAL CARE DE GMBH , ZHANG WEI , SCHULTE ELKE , KAISER MARTIN , MUELLER CARSTEN , KLEIN TOM , ZERLE STEFAN , BARDORZ CHRISTOPH , STUEHLER STEFAN
发明人： ZHANG WEI , SCHULTE ELKE , KAISER MARTIN , MUELLER CARSTEN , KLEIN TOM , ZERLE STEFAN , BARDORZ CHRISTOPH , STUEHLER STEFAN
IPC分类号： A61B5/145 , A61B5/1455
CPC分类号： G01N33/49 , A61B5/14557 , A61M1/367 , A61M2205/14 , A61M2205/3306 , A61M2230/20 , G01N21/05 , G01N21/31 , G01N2021/0378 , G01N2021/3144
摘要： The invention relates to a device for determining the concentration of a blood constituent in a tube line, in particular in the tube line of an extracorporeal blood circuit of an extracorporeal blood treating device. The invention further relates to a method for detecting a tube line, in particular a tube line of an extracorporeal blood circuit of an extracorporeal blood treating device, in a clamping unit of a device for determining the concentration of a blood constituent in the tube line. The device for determining the concentration of a blood constituent in a tube line of an extracorporeal blood circuit is characterized by a clamping unit (12) that has an actuating mechanism (18) which is designed such that a first and second receiving element (15, 16) can be moved relative to each other from a first position that releases the tube line into a second position that clamps the tube line by applying a clamping force, said actuating mechanism being driven by an electric motor (19). The device according to the invention is further characterized by a monitoring unit (27) that is designed such that the tube line (17) placed into the receiving elements (15, 16) can be detected. Thus, an automation of the blood parameter measuring process is possible.
摘要翻译：本申请涉及一种用于确定血液的成分的浓度中的软管线，特别是在体外血液处理装置的体外血液回路的管道。此外，本申请涉及一种用于检测一个软管线的，在体外血液处理装置的体外血液回路的特定的软管线，在一个装置的夹持单元，用于确定在所述管道血液成分的浓度。用于确定在体外血液回路的软管管线的血液成分的浓度的装置的特征在于具有一个致动机构（18），其被设计为使得，下的偏置力（应用第一和第二接收元件的夹持单元（12） 15，16）是一第一软管线释放在第二位置的位置管夹持端彼此抵靠可移动的，其中所述致动机构的驱动用的电动机（19）。此外，根据本发明的装置是由被形成为使得在所述接收元件（15，16）插入软管（17）中可以看出的监测单元（27）区分。血液参数测量的自动化是可能的。

57. 发明申请

WO2013017194A3 METHOD FOR DETERMINING AT LEAST ONE PARAMETER OF AN EXTRACORPOREAL BLOOD CIRCUIT, AND DEVICES 审中-公开
标题翻译：用于确定至少一个方法参数的体外血液回路DEVICES
公开(公告)号：WO2013017194A3
公开(公告)日：2013-04-04
申请号：PCT/EP2012002908
申请日：2012-07-10
申请人： FRESENIUS MEDICAL CARE DE GMBH , NOACK JOACHIM , ZHANG WEI
发明人： NOACK JOACHIM , ZHANG WEI
IPC分类号： A61M1/36
CPC分类号： A61M1/3643 , A61M1/3644 , A61M2205/3306 , A61M2205/3368 , A61M2205/3375 , A61M2205/3379 , A61M2205/3393 , Y10T137/0318
摘要： The present invention relates to a method for determining at least one parameter of an extracorporeal blood circuit (1000), said method having the following steps: an extracorporeal blood circuit (1000), e.g. comprising a medical functional appliance (100) and/or a treatment appliance (200) and/or a blood hose set, is filled by introduction of a (medical) fluid; and a volume of the introduced fluid needed to fill the extracorporeal blood circuit (1000) is detected by means of a detection appliance. The invention further relates to a control appliance (27), a treatment device, a digital storage medium, a computer program product, and a computer program.
摘要翻译：本发明涉及一种用于确定体外血液回路（1000）包括以下步骤中的至少一个参数：体外血液回路（1000）的填充，例如。 B.包括医疗功能的装置（100）和/或处理装置（200）和/或血液管通过引入（医疗）流体集; 并检测所需要用于填充体外血液回路（1000）所引入的流体的体积，由检测装置的装置。本发明还涉及一种控制装置（27），处理装置，数字存储介质，计算机程序产品和计算机程序。

58. 发明申请

WO2011157142A3 METHOD AND APPARATUS FOR MESSAGE TRANSMISSION 审中-公开
标题翻译：消息传输的方法和装置
公开(公告)号：WO2011157142A3
公开(公告)日：2012-04-26
申请号：PCT/CN2011075041
申请日：2011-05-31
申请人： HUAWEI TECH CO LTD , UNIV TSINGHUA , BI JUN , WANG YOU , ZHANG WEI , HU HONGYU , WANG YANGYANG
发明人： BI JUN , WANG YOU , ZHANG WEI , HU HONGYU , WANG YANGYANG
IPC分类号： H04W4/12 , H04W12/00
CPC分类号： H04W8/08 , H04W12/06
摘要： A method and an apparatus for message transmission, which relate to a communications field, are provided in the embodiments of the present invention. The method includes: receiving an authentication request from a first user equipment, and transmitting, according to a first User Identifier (UID), an authentication request for user binding to a Home Subscriber Server (HSS) for the first user, in order that the HSS for the first user judges, according to a saved binding relationship between an International Mobile Subscriber Identity (IMSI) and the UID, whether a binding relationship between the IMSI of the first user equipment and the first UID is legal; and if the HSS for the first user determines that the binding relationship between the IMSI of the first user equipment and the first UID is legal, downloading the binding relationship between the IMSI of the first user equipment and the first UID from the HSS for the first user, and after establishing communications between the first user equipment and a second user equipment, transmitting a message satisfying the downloaded binding relationship to the second user equipment when receiving the message from the first user equipment. In the present invention, the occurrence of the UID fabrication in the data transmission procedure is prevented, and the security of the data transmission is enhanced.
摘要翻译：在本发明的实施例中提供了一种与通信领域相关的消息传输的方法和装置。该方法包括：从第一用户设备接收认证请求，并根据第一用户标识符（UID）发送用户绑定到第一用户的归属订户服务器（HSS）的认证请求，以便第一用户的HSS根据国际移动用户身份（IMSI）和UID之间的保存的绑定关系来判断第一用户设备的IMSI与第一UID之间的绑定关系是否合法; 并且如果第一用户的HSS确定第一用户设备的IMSI与第一UID之间的绑定关系合法，则从第一用户设备的HSS到第一用户设备的IMSI之间的绑定关系下载第一用户设备的IMSI与第一UID之间的绑定关系并且在建立第一用户设备和第二用户设备之间的通信之后，当从第一用户设备接收到消息时，向第二用户设备发送满足下载的绑定关系的消息。在本发明中，防止在数据传输过程中出现UID制造，提高了数据传输的安全性。

59. 发明申请

WO2010115621A3 DEVICE AND METHOD FOR MEASURING A BLOOD CONSTITUENT IN BLOOD FOR AN EXTRACORPOREAL BLOOD TREATMENT DEVICE 审中-公开
标题翻译：设备和方法测量血液成分在血液血液处理装置张福亭
公开(公告)号：WO2010115621A3
公开(公告)日：2010-12-23
申请号：PCT/EP2010002188
申请日：2010-04-08
申请人： FRESENIUS MEDICAL CARE DE GMBH , ZHANG WEI
发明人： ZHANG WEI
IPC分类号： A61B5/00 , A61M1/16
CPC分类号： A61M1/16 , A61B5/14532 , A61B5/14557 , A61M1/3609 , A61M1/361 , A61M2205/3317 , A61M2205/3324 , A61M2230/30
摘要： The invention relates to a device and a method for measuring a blood constituent in blood for an extracorporeal blood treatment device, comprising a dialyzer (1) which is separated into a first chamber (3) and a second chamber (4) by a semi-permeable membrane (2), or comprising a filter, and a hose line system (I, II) comprising hose lines (5, 7; 10, 11) that are pervious to electromagnetic radiation. The invention is based on the fact that the kinetics of a liquid flowing at a measuring site in one of the hose lines (5) of the hose line system (I) is varied. This can be achieved by varying the flow properties of the liquid in the hose line at the measuring site, particularly by stopping a blood pump (6) arranged in the hose line (5) and/or by closing a shut-off member (22) in the hose line. The actual analysis of the measuring data obtained for determining the concentration of the blood constituent is then carried out according to the known methods that use a pressure cuff at the finger of the patient, wherein the invention however analyzes the intensity of the light entering the hose line (5) at the measuring site and the light exiting the hose line at the measuring site.
摘要翻译：本发明涉及一种装置和用于测量血液中的血液成分用于体外血液处理装置，包括一由半透膜（2）成第一腔室（3）和第二室（4）划分的透析器（1）或过滤器的方法，和一个管道系统（I，II），这是透过电磁辐射软管线（5,7; 10，11）。本发明是基于在其上的，即在在软管的一个一个测量点的动力学（5）的软管管线系统（I）流动的液体的被改变。（5）布置在所述血泵这可通过在软管线停止改变液体的流动特性在测量点处的软管线，特别是进行（6）和/或在软管管线关闭关闭装置（22）。所获得的测量数据的实际分析，以确定血液成分然后通过已知方法进行的浓度，利用一个压力袖带的患者，本发明的一个手指，但是，在测量点处，并从进入的强度在软管管路（5）在测量点处射光分析软管线。

60. 发明申请

WO2010048530A3 METHODS AND COMPOSITIONS EMPLOYING AN IIP45 TARGETING LIGAND 审中-公开
标题翻译：采用IIP45靶向配体的方法和组合物
公开(公告)号：WO2010048530A3
公开(公告)日：2010-08-19
申请号：PCT/US2009061889
申请日：2009-10-23
申请人： RES DEV FOUNDATION , UNIV TEXAS , ROSENBLUM MICHAEL G , CHEUNG LAWRENCE H , FULLER GREGORY , ZHANG WEI
发明人： ROSENBLUM MICHAEL G , CHEUNG LAWRENCE H , FULLER GREGORY , ZHANG WEI
IPC分类号： C07K19/00 , A61P35/00
CPC分类号： C07K14/4703
摘要： ethods and composition for the targeted delivery using targeting conjugates comprising different domains of IIP45 are described. Furthermore, the invention provides targeting conjugates comprising therapeutic agents or diagnostic agents incorporating IIP45 as a targeting ligand for delivery to cells or tissues, such as tumor.
摘要翻译：描述了使用包含IIP45的不同结构域的靶向缀合物进行靶向递送的方法和组合物。此外，本发明提供了包含治疗剂或诊断剂的靶向缀合物，其掺入IIP45作为用于递送至细胞或组织（例如肿瘤）的靶向配体。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式